English
GlaxoSmithKline Pharmaceuticals Q4 Results
- BSE: 500660
- NSE: GLAXO
- ISIN: INE159A01016
- Sector: Biotechnology & Drugs
BSE
2,536.00
-54.55 (-2.11%)
-54.55 (-2.11%)Volume2.07 K
Updated: Mon 10 Nov, 2025 | 15:29:13
NSE
2,539.80-48.10 (-1.86%)
-48.10 (-1.86%)Volume59.27 K
Updated: Mon 10 Nov, 2025 | 15:52:18
Technical Trends
Long TermConsiders price movement over the last 6 months
Not Available
Short TermConsiders price movement over the last 1-2 weeks
Not Available
- Bearish
- Moderately Bearish
- Neutral
- Moderately Bullish
- Bullish
Insight: Trends unavailable at the moment.
Q4 Results Highlights
Note: Comparison is on QoQ basis
Quarterly - GlaxoSmithKline Pharmaceuticals Q4 Results
*All figures in crores except per share values
| Fiscal Period | Mar 25 | Dec 24 | QoQ Comp | Mar 24 | YoY Comp |
|---|---|---|---|---|---|
| Total Operating Expense | 655.90 | 676.30 | -3.02% | 690.63 | -5.03% |
| Depreciation/ Amortization | 14.72 | 18.80 | -21.69% | 18.10 | -18.66% |
| Operating Income | 318.47 | 273.12 | 16.60% | 239.17 | 33.16% |
| Net Income | 262.87 | 229.88 | 14.35% | 194.48 | 35.17% |
| Other Operating Expenses Total | 136.27 | 173.60 | -21.50% | 132.58 | 2.78% |
| Net Income Before Taxes | 358.57 | 308.10 | 16.38% | 270.62 | 32.50% |
| Total Revenue | 974.37 | 949.42 | 2.63% | 929.80 | 4.79% |
| Selling/ General/ Admin Expenses Total | 152.97 | 124.74 | 22.63% | 172.83 | -11.49% |
| Diluted Normalized EPS | 15.51 | 13.57 | 14.33% | 11.37 | 36.43% |